Key Drivers
- Low Leverage
- Negative Cash Flow
- Heavy R&D
AIAI Summary
PCVX is a cash-rich but highly binary clinical-event investment: VAX-31's late-October 2026 OPUS-1 data could validate its potential ~95% strain coverage advantage and drive a major rerating, while any safety, tolerability, or immunogenicity shortfall would undermine its core value despite ample runway. Investors should size exposure around this catalyst and monitor $58 support, cash burn, and whether positive data can translate into credible competitive differentiation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Low Leverage
- •Negative Cash Flow
- •Heavy R&D
PCVX has a strong cash and investment base with low leverage, but persistent losses, heavy R&D spending, negative free cash flow, and declining liquidity make it a high-risk, cash-burn investment.
Price Behavior
Key Price Behavior Insights:
- •Below averages
- •$58 support
- •Weak momentum
PCVX is bearish over the last month below key moving averages, with $58 support critical and a rebound requiring a move above $60.35–$61.20.
Sharp rise from $53.53 to $63.30 in early-to-mid
Sentiment & News
Key News Insights:
- •Strong Cash Runway
- •Institutional Buying
- •Options Caution
Vaxcyte's strong cash position and growing institutional support bolster its clinical-data runway, though ongoing losses and elevated put activity signal near-term caution.
The news is broadly supportive for Vaxcyte's long-term outlook but may leave shares volatile ahead of VAX-31 data
Similar Companies in Healthcare
Other companies in the same sector with AI ratings